Form 497VPU VARIABLE ANNUITY LIFE
SUPPLEMENT DATED OCTOBER 30, 2026
TO THE PROSPECTUSES AND SUMMARY
PROSPECTUSES, EACH DATED May 1, 2026
THE VARIABLE ANNUITY LIFE INSURANCE COMPANY
SEPARATE ACCOUNT A
Fixed and Variable Deferred Annuity Contracts
Potentia®
This supplement updates certain information for the above referenced prospectus, updating summary prospectus, and initial summary prospectus (collectively, the “Prospectus”). Except as indicated in this supplement, all other information included in the Prospectus and Appendix A, including the footnotes, remains unchanged. You should read this supplement in conjunction with your Prospectus and retain it for future reference. All capitalized terms used but not defined herein have the same meaning as those included in the Prospectus.
In the “Key Information” section in the prospectus and the “Important Information You Should Consider About the Contract” section in the Initial Summary Prospectus and the Updating Summary Prospectus, the following changes are made:
| | In the “Are There Ongoing Fees and Expenses?” section of the “FEES AND EXPENSES” table, the minimum fee for Investment Options is 0.19% and the Lowest Cost is $1,668. Additionally, the maximum fee for Investment Options is 0.99% and the Highest Annual Cost is $2,471. |
In the “Fee Table” section in the prospectus and the “Additional Information About Fees” section in the Initial Summary Prospectus, the following changes are made:
| | In the “Annual Portfolio Company Expenses” table, the minimum Annual Fund Expenses is 0.19% and the maximum Annual Fund Expenses is 0.99%. |
| | In the “Examples” section, the following replaces the expense examples: |
The first set of examples assumes the most expensive combination of annual Contract expenses and annual Fund expenses. Based on these assumptions, your costs would be:
(1) If you surrender your Contract at the end of the applicable time period:
| 1 Year | 3 Years | 5 Years | 10 Years | |||
|
$2,471 |
$7,608 | $13,014 | $27,804 | |||
(2) If you annuitize your Contract or you do not surrender your Contract:
| 1 Year | 3 Years | 5 Years | 10 Years | |||
|
$2,471 |
$7,608 | $13,014 | $27,804 | |||
The second set of examples assumes the least expensive combination of annual Contract expenses and annual Fund expenses. Based on these assumptions, your costs would be:
(1) If you surrender your Contract at the end of the applicable time period:
| 1 Year | 3 Years | 5 Years | 10 Years | |||
|
$1,668 |
$5,176 | $8,927 | $19,487 | |||
Page 1 of 3
(2) If you annuitize your Contract or you do not surrender your Contract:
| 1 Year | 3 Years | 5 Years | 10 Years | |||
| $1,668 | $5,176 | $8,927 | $19,487 | |||
The following table replaces the current table in its entirety in Appendix A:
|
Type/Investment Objective |
Portfolio Company and Adviser/ Subadviser(s)1 |
Current Expenses |
Platform Charge4 |
Current Expenses + Platform Charge |
Average Annual Total Returns (as of Dec. 31, 2025) | |||||||||
| 1 Year | 5 Year |
10 Year (or life of fund) | ||||||||||||
|
Domestic Large-Cap Equity |
Capital Appreciation Fund2 Adviser: VALIC Sub-Adviser: Columbia Management Investment Advisers, LLC
|
0.68% | None | 0.68% | 14.19% | 14.69% | 15.33% | |||||||
| Growth Fund2, 3 Adviser: VALIC Sub-Advisers: BlackRock Investment Management, LLC
|
0.61% | None | 0.61% | 14.57% | 11.57% | 15.67% | ||||||||
| Large Cap Core Fund2 Adviser: VALIC Sub-Adviser: JPMIM and T. Rowe Price
|
0.68% | None | 0.68% | 9.81% | 10.02% | 14.27% | ||||||||
| Stock Index Fund2, 3 Adviser: VALIC Sub-Adviser: BlackRock
|
0.22% | None | 0.22% | 17.55% | 14.08% | 14.46% | ||||||||
| Systematic Core Fund2, 3 Adviser: VALIC Sub-Adviser: Goldman Sachs Asset Management, L.P.
|
0.63% | None | 0.63% | 14.77% | 12.45% | 13.89% | ||||||||
|
Domestic Mid- Cap Equity |
Mid Cap Index Fund2 Adviser: VALIC Sub-Adviser: BlackRock
|
0.36% | None | 0.36% | 6.95% | 8.68% | 10.34% | |||||||
| Mid Cap Strategic Growth Fund2 Adviser: VALIC Sub-Advisers: Janus Henderson Investors US LLC and Voya Investment Management Co. LLC
|
0.73% | None | 0.73% | 11.34% | 7.88% | 13.56% | ||||||||
|
Domestic Small-Cap Equity |
Small Cap Growth Fund2, 3 Adviser: VALIC Sub-Advisers: American Century Investment Management, Inc. and T. Rowe Price Associates, Inc.
|
0.88% | None | 0.88% | 9.20% | -2.35% | 11.01% | |||||||
| Small Cap Index Fund2, 3 Adviser: VALIC Sub-Adviser: BlackRock
|
0.36% | None | 0.36% | 12.23% | 5.69% | 9.27% | ||||||||
|
Global Equity (International and Domestic)
|
International Socially Responsible Fund2, 3 Adviser: VALIC Sub-Adviser: BlackRock
|
0.57% | None | 0.57% | 27.32% | 7.80% | 9.10% | |||||||
|
International Equity |
Emerging Economies Fund2 Adviser: VALIC Sub-Adviser: BlackRock
|
0.99% | None | 0.99% | 30.11% | 4.19% | 8.04% | |||||||
|
Specialty |
Science & Technology Fund2, 3 Adviser: VALIC Sub-Advisers: BlackRock, Voya
|
0.91% | None | 0.91% | 22.57% | 11.59% | 18.92% | |||||||
Page 2 of 3
|
Type/Investment Objective |
Portfolio Company and Adviser/ Subadviser(s)1 |
Current Expenses |
Platform Charge4 |
Current Expenses + Platform Charge |
Average Annual Total Returns (as of Dec. 31, 2025) | |||||||||
| 1 Year | 5 Year |
10 Year (or life of fund) | ||||||||||||
|
Hybrid (Equity and Fixed Income) |
Aggressive Allocation Lifestyle Fund2, 3 Adviser: VALIC Sub-Adviser: JPMIM
|
0.56% | None | 0.56% | 16.94% | 8.73% | 9.38% | |||||||
| Conservative Allocation Lifestyle Fund2, 3 Adviser: VALIC Sub-Adviser: JPMIM
|
0.60% | None | 0.60% | 11.79% | 4.34% | 5.85% | ||||||||
| Moderate Allocation Lifestyle Fund2, 3 Adviser: VALIC Sub-Adviser: JPMIM
|
0.57% | None | 0.57% | 14.40% | 7.01% | 8.10% | ||||||||
|
Fixed Income |
Core Bond Fund2 Adviser: VALIC Sub-Advisers: PineBridge Investments LLC and JPMIM
|
0.48% | None | 0.48% | 7.64% | -0.16% | 2.36% | |||||||
| Goldman Sachs VIT Government Money Market Fund3 – Institutional Shares Adviser: Goldman Sachs |
0.18% | None | 0.18% | 4.20% | 3.18% | 2.11% | ||||||||
Page 3 of 3
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Gecina: Information Regarding the Total Voting Rights and Shares of Gecina as of October 31, 2026 (1)
- Coloplast A/S Announcement no. 11/2026 - 2025/26 Full-Year Financial Results
- Progress Trial Demonstrates Edwards TAVR Is Superior to Clinical Surveillance for Moderate AS Patients With At-Risk Features
Create E-mail Alert Related Categories
SEC FilingsSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!




Tweet
Share